Literature DB >> 22157622

The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

Craig Horbinski1, Marina N Nikiforova, Jonathan Hobbs, Stephanie Bortoluzzi, Kathleen Cieply, Sanja Dacic, Ronald L Hamilton.   

Abstract

1p/19q codeletion is a favorable prognostic marker of oligodendrogliomas. Although fluorescence in situ hybridization (FISH) and microsatellite-based polymerase chain reaction (PCR) for loss of heterozygosity (LOH) are common methods to test for 1p/19q codeletion, it is unclear which test is better at prognostic stratification. This study analyzed outcomes of 111 oligodendrogliomas with both 1p/19q FISH and LOH done at the time of diagnosis. Overall concordance between the 2 assays was 81.1%. In grade III oligodendrogliomas, LOH was better than FISH at survival stratification (p < 0.0001 for LOH vs p = 0.02 for FISH), although increasing the stringency of FISH interpretation criteria improved concordance and prognostic power. Oligodendrogliomas that were 1p/19q-codeleted by FISH but also had 10q LOH were negative for 1p/19q codeletion by PCR analysis in more than 70% of cases, with very poor survival in the grade III subset. Thus, although PCR-based LOH is a better stratifier of 1p/19q status, FISH still has clinical and prognostic utility, especially if 10q data can be incorporated.

Entities:  

Mesh:

Year:  2012        PMID: 22157622      PMCID: PMC3246063          DOI: 10.1097/NEN.0b013e318240fa65

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  47 in total

1.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Pediatric oligodendrogliomas: a study of molecular alterations on 1p and 19q using fluorescence in situ hybridization.

Authors:  Ravi Raghavan; Jyoti Balani; Arie Perry; Linda Margraf; Mary B Vono; Dan X Cai; Robert E Wyatt; Elisabeth J Rushing; Daniel C Bowers; Linda S Hynan; Charles L White
Journal:  J Neuropathol Exp Neurol       Date:  2003-05       Impact factor: 3.685

3.  PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.

Authors:  H Sasaki; M C Zlatescu; R A Betensky; Y Ino; J G Cairncross; D N Louis
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas.

Authors:  Craig Horbinski; Ronald L Hamilton; Yuri Nikiforov; Ian F Pollack
Journal:  Acta Neuropathol       Date:  2010-01-01       Impact factor: 17.088

5.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype.

Authors:  J S Smith; B Alderete; Y Minn; T J Borell; A Perry; G Mohapatra; S M Hosek; D Kimmel; J O'Fallon; A Yates; B G Feuerstein; P C Burger; B W Scheithauer; R B Jenkins
Journal:  Oncogene       Date:  1999-07-15       Impact factor: 9.867

6.  Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.

Authors:  Iris Lavon; Daniel Zrihan; Bracha Zelikovitch; Yakov Fellig; Dana Fuchs; Dov Soffer; Tali Siegal
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

7.  Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.

Authors:  Carmen Franco-Hernández; Victor Martínez-Glez; Jose M de Campos; Alberto Isla; Jesús Vaquero; Manuel Gutiérrez; Cacilda Casartelli; Juan A Rey
Journal:  Cancer Genet Cytogenet       Date:  2009-04-15

8.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

Authors:  J Reifenberger; G Reifenberger; L Liu; C D James; W Wechsler; V P Collins
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa).

Authors:  John K Cowell; Gene H Barnett; Norma J Nowak
Journal:  J Neuropathol Exp Neurol       Date:  2004-02       Impact factor: 3.685

10.  IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 13.801

View more
  17 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

Review 2.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

3.  A multi-institutional analysis of clinical outcomes and patterns of care of 1p/19q codeleted oligodendrogliomas treated with adjuvant or salvage radiation therapy.

Authors:  Alexander J Lin; Liam T Kane; Jason K Molitoris; Deborah R Smith; Sonika Dahiya; Shahed N Badiyan; Tony J C Wang; Tim J Kruser; Jiayi Huang
Journal:  J Neurooncol       Date:  2019-11-18       Impact factor: 4.130

4.  Molecular Analysis of Pediatric Oligodendrogliomas Highlights Genetic Differences with Adult Counterparts and Other Pediatric Gliomas.

Authors:  David Nauen; Lisa Haley; Ming-Tseh Lin; Arie Perry; Caterina Giannini; Peter C Burger; Fausto J Rodriguez
Journal:  Brain Pathol       Date:  2015-08-14       Impact factor: 6.508

5.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

6.  How molecular testing can help (and hurt) in the workup of gliomas.

Authors:  Kenneth Clark; Zoya Voronovich; Craig Horbinski
Journal:  Am J Clin Pathol       Date:  2013-03       Impact factor: 2.493

Review 7.  Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management.

Authors:  Solmaz Sahebjam; Mairéad G McNamara; Warren P Mason
Journal:  CNS Oncol       Date:  2013-07

8.  1p/19q testing has no significance in the workup of glioblastomas.

Authors:  K H Clark; J L Villano; M N Nikiforova; R L Hamilton; C Horbinski
Journal:  Neuropathol Appl Neurobiol       Date:  2013-10       Impact factor: 8.090

9.  A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.

Authors:  Rebecca Senetta; Ludovica Verdun di Cantogno; Luigi Chiusa; Isabella Castellano; Patrizia Gugliotta; Anna Sapino; Paola Cassoni
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

Review 10.  Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.

Authors:  Sebastian Brandner; Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Neuropathol Appl Neurobiol       Date:  2022-03-03       Impact factor: 6.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.